Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in Oregon: - Saint Alphonsus Cancer Care Center-Baker City — Baker City, Oregon
- Saint Charles Health System — Bend, Oregon
- Clackamas Radiation Oncology Center — Clackamas, Oregon
- Providence Cancer Institute Clackamas Clinic — Clackamas, Oregon
- Bay Area Hospital — Coos Bay, Oregon
Phase 3 Recruiting Academic/Other
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radi…
Sponsor: NRG Oncology
NCT ID: NCT04852887
Sites in Oregon: - Clackamas Radiation Oncology Center — Clackamas, Oregon
- Providence Cancer Institute Clackamas Clinic — Clackamas, Oregon
- Legacy Mount Hood Medical Center — Gresham, Oregon
- Providence Newberg Medical Center — Newberg, Oregon
- Providence Willamette Falls Medical Center — Oregon City, Oregon
Phase 3 Recruiting Academic/Other
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Sites in Oregon: - Saint Charles Health System — Bend, Oregon
- Three Rivers Community Hospital — Grants Pass, Oregon
- Legacy Mount Hood Medical Center — Gresham, Oregon
- Providence Hood River Memorial Hospital — Hood River, Oregon
- Asante Rogue Regional Medical Center — Medford, Oregon
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Oregon: - Clackamas Radiation Oncology Center — Clackamas, Oregon
- Legacy Mount Hood Medical Center — Gresham, Oregon
- Legacy Good Samaritan Hospital and Medical Center — Portland, Oregon
- Providence Portland Medical Center — Portland, Oregon
- Providence Saint Vincent Medical Center — Portland, Oregon
Phase 3 Recruiting Industry
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which inc…
Sponsor: Gilead Sciences
NCT ID: NCT05633654
Sites in Oregon: - St. Charles Health System, Inc. DBA St. Charles Medical Center — Bend, Oregon
- Samaritan Hospital — Corvallis, Oregon
- Willamette Valley Cancer Institute and Research Center — Eugene, Oregon
- Asante Rogue Regional Medical Center — Medford, Oregon
- Providence Cancer Institute - Oncology Clinical Trials — Portland, Oregon
Phase 3 Recruiting Industry
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early b…
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT06492616
Sites in Oregon: - Providence Cancer Institute Franz Clinic — Portland, Oregon
- Oregon Oncology Specialists — Salem, Oregon
- Northwest Cancer Specialists, P.C. — Tigard, Oregon
Phase 3 Recruiting Industry
The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBC…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05827081
Sites in Oregon: - Good Samaritan Regional Medical Center — Corvallis, Oregon
- Oncology Associates of Oregon PC — Eugene, Oregon
- Northwest Cancer Specialists — Portland, Oregon
- Oregon Oncology Specialists Salem — Salem, Oregon
Phase 3 Recruiting Industry
This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribo…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06065748
Sites in Oregon: - Asante Rogue Regional Medical Center — Medford, Oregon
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in th…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06966700
Sites in Oregon: - Northwest Cancer Specialists (Compass Oncology) ( Site 8010) — Tigard, Oregon
Phase 3 Recruiting Industry
This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participant…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06790693
Sites in Oregon: - Providence Portland Medical Center — Portland, Oregon
- Providence Oncology and Hematology Cancer Clinic - Westside;Investigation Drug Services Pharmacy — Portland, Oregon
Phase 3 Recruiting Industry
This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have complete…
Sponsor: Greenwich LifeSciences, Inc.
NCT ID: NCT05232916
Sites in Oregon: - Hematology Oncology Associates — Medford, Oregon
- Compass Oncology - Northwest Cancer Specialists — Tigard, Oregon
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Oregon: - Providence Newberg Medical Center — Newberg, Oregon
- Saint Alphonsus Cancer Care Center-Ontario — Ontario, Oregon
- Providence Willamette Falls Medical Center — Oregon City, Oregon
- Providence Portland Medical Center — Portland, Oregon
- Providence Saint Vincent Medical Center — Portland, Oregon
Phase 2 Recruiting Academic/Other
This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.
Sponsor: Oana Danciu
NCT ID: NCT05467891
Sites in Oregon: - Providence Portland Medical Center — Portland, Oregon
Phase 1, Phase 2 Recruiting Industry
This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that has recurr…
Sponsor: AstraZeneca
NCT ID: NCT05417594
Sites in Oregon: - Research Site — Portland, Oregon
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a fi…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT04895709
Sites in Oregon: - Providence Cancer Center Oncology and Hematology Care- Eastside — Portland, Oregon
Phase 2 Recruiting Academic/Other
The usual approach to care for hormone receptor positive, HER2 positive breast cancer is chemotherapy and HER2 targeted therapy followed by endocrine therapy and surgery. The purpose of this Research Study is to see if taking endocrine the…
Sponsor: Legacy Health System
NCT ID: NCT07506876
Sites in Oregon: - Legacy Mount Hood Medical Center — Gresham, Oregon
- Legacy Good Samaritan Medical Center — Portland, Oregon
- Legacy Meridian Park Medical Center — Tualatin, Oregon
Phase 2 Recruiting Academic/Other
This phase II trial investigates how well 177Lu-DOTATATE works in treating patients with breast cancer that is stage IV or has come back (recurrent). 177Lu-DOTATATE may shrink or destroy the tumor or circulating breast cancer stem cells if…
Sponsor: OHSU Knight Cancer Institute
NCT ID: NCT04529044
Sites in Oregon: - OHSU Knight Cancer Institute — Portland, Oregon
Phase 1 Recruiting Industry
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
Sponsor: Iambic Therapeutics, Inc
NCT ID: NCT06253871
Sites in Oregon: - Providence Cancer Institute — Portland, Oregon
Phase 1 Recruiting Industry
This study is a multiple cohort, multicenter, open-label Phase 1 study with dose-escalation substudies investigating intravenous (IV) BAL0891 as monotherapy, and in combination with tislelizumab or paclitaxel, to determine the safety and t…
Sponsor: SillaJen, Inc.
NCT ID: NCT05768932
Sites in Oregon: - OHSU Knight Cancer Institute — Portland, Oregon
Phase 1 Recruiting Industry
This is a first-in-human, multicenter, open-label, phase 1 study to evaluate safety, tolerability, and efficacy of CID-078, a Cyclin A/B-RxL inhibitor, in patients with advanced solid tumors.
Sponsor: Circle Pharma
NCT ID: NCT06577987
Sites in Oregon: - Oregon Health and Science University — Portland, Oregon
Phase 1 Recruiting Industry
The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tu…
Sponsor: MacroGenics
NCT ID: NCT06242470
Sites in Oregon: - Providence Cancer Institute — Portland, Oregon
Phase 1 Recruiting Academic/Other
The goal of this study is to plan for a large scale evaluation of a program called Mindful After Cancer, or MAC. The MAC Program provides training in mindfulness, educational material about sexual health after cancer, and support to cancer…
Sponsor: Oregon State University
NCT ID: NCT07055854
Sites in Oregon: - Samaritan Pastega Regional Cancer Center — Corvallis, Oregon
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Oregon: - Saint Alphonsus Cancer Care Center-Baker City — Baker City, Oregon
- Saint Alphonsus Cancer Care Center-Ontario — Ontario, Oregon
- Kaiser Permanente Northwest — Portland, Oregon
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Oregon: - Massive Bio SYNERGY-AI site — Portland, Oregon
Recruiting Industry
This is a prospective, non-interventional (observational) cohort study conducted within the medical network of the participating investigators and institutions. Patients meeting the eligibility criteria (see below) will be eligible for par…
Sponsor: PreludeDx
NCT ID: NCT03448926
Sites in Oregon: - Compass Oncology — Tigard, Oregon